Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, England, UK.
J Exp Med. 2014 Feb 10;211(2):181-8. doi: 10.1084/jem.20131189. Epub 2014 Feb 3.
The erythroid stress cytokine erythropoietin (Epo) supports the development of committed erythroid progenitors, but its ability to act on upstream, multipotent cells remains to be established. We observe that high systemic levels of Epo reprogram the transcriptomes of multi- and bipotent hematopoietic stem/progenitor cells in vivo. This induces erythroid lineage bias at all lineage bifurcations known to exist between hematopoietic stem cells (HSCs) and committed erythroid progenitors, leading to increased erythroid and decreased myeloid HSC output. Epo, therefore, has a lineage instructive role in vivo, through suppression of non-erythroid fate options, demonstrating the ability of a cytokine to systematically bias successive lineage choices in favor of the generation of a specific cell type.
红细胞应激细胞因子促红细胞生成素(Epo)支持定向红系祖细胞的发育,但它作用于上游多能细胞的能力尚待确定。我们观察到,体内高浓度的 Epo 可重新编程多能和双能造血干/祖细胞的转录组。这导致在已知存在于造血干细胞(HSCs)和定向红系祖细胞之间的所有谱系分叉处偏向红细胞系,导致红系 HSC 输出增加和髓系 HSC 输出减少。因此,Epo 在体内具有谱系指导作用,通过抑制非红细胞系命运选择,证明了细胞因子系统地偏向连续谱系选择以有利于特定细胞类型生成的能力。